soul trial oral semaglutide cardiovascular outcomes The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial | Heart Failure Reviews

Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

24.45

★★★★☆4.8 (126)

Full article: Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients

27.34

★★★★★4.9 (98)

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

20.99

★★★★★5.0 (157)

PDF) Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial

25.07

★★★★★4.7 (84)

Novo Nordisk's Semaglutide lowers MACE risk in SOUL trial

23.50

★★★★★4.9 (203)

A secondary analysis of the SOUL trial showed that oral semaglutide, like the injected form, improves outcomes related to heart failure in high-risk patients with diabetes

26.28

★★★★★5.0 (176)

Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies

24.24

★★★★★4.8 (132)